While prognoses for prostate cancer patients were once measured in months, experts say that advances in treatment and diagnosis now improve survival by years. By Gina Kolata Prostate cancer experts ...
Talzenna plus Xtandi showed a 14-month survival improvement for HRR gene-mutated metastatic castration-resistant prostate cancer, supported by TALAPRO-2 trial data. Nubeqa approval for metastatic ...
A new treatment strategy tested by UCLA researchers could offer new hope for men whose prostate cancer has returned after initial treatment. This approach could also help delay the need for hormone ...
Hosted on MSN
After telling the world I have prostate cancer, your prayers, support and testimony lifted me
This is an opinion column. Get my weekly newsletter, The Barbershop. Sign up here for free! Writers write. We do what we do. We do what we do with purpose and passion — not always knowing the ...
Learn the key warning signs of prostate cancer that men often overlook. Early awareness can make all the difference.
I am a prostate cancer patient and a board-certified health care chaplain. I’ve served patients from every end of the spectrum. And I’m living with hormone-sensitive, high-grade (Gleason 9) prostate ...
The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival ...
In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...
Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment. A recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results